Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis

@article{Newhook2016AdjuvantTD,
  title={Adjuvant Trametinib Delays the Outgrowth of Occult Pancreatic Cancer in a Mouse Model of Patient-Derived Liver Metastasis},
  author={Timothy E. Newhook and James M. Lindberg and Sara J. Adair and Alison J. Kim and Edward B. Stelow and Osama E. Rahma and J. Thomas Parsons and Todd W. Bauer},
  journal={Annals of Surgical Oncology},
  year={2016},
  volume={23},
  pages={1993-2000}
}
PurposeMost patients with pancreatic ductal adenocarcinoma (PDAC) die within 5 years following resection plus adjuvant gemcitabine (Gem) from outgrowth of occult metastases. We hypothesized that inhibition of the KRAS pathway with the MEK inhibitor trametinib would inhibit the outgrowth of occult liver metastases in a preclinical model.MethodsLiver metastases harvested from two patients with PDAC (Tumors 608, 366) were implanted orthotopically in mice. Tumor cell lines were derived and… CONTINUE READING
Highlighted Tweets
This paper has been referenced on Twitter 3 times. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES